RELEASE DISCLOSURE OF TRADING IN OWN SHARES FROM APRIL 21 TO APRIL 25, 2025 In accordance with the authorization granted by the Shareholders’ Meeting in order to trade in own shares and pursuant to applicable law on share repurchases, Rexel declares the following purchases of its own shares from April 21 to April 25, 2025: Name of the issuerIdentity code of the issuer (Legal Entity Identifier)Day of transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted ...

Core Viewpoint - VINCI is launching a tap issue of non-dilutive convertible bonds for a nominal amount of €125 million, which may be increased to €150 million, to be fully assimilated with its existing €400 million non-dilutive convertible bonds due February 2030 [1][2] Group 1: Bond Issuance Details - The New Bonds will be issued on the same terms as the Original Bonds, with the exception of the issue date and price, and will be fully fungible with the Original Bonds upon settlement [2] - The initial issue price of the New Bonds is expected to be between 106.450% and 106.950% of their nominal value, with the final price to be announced on 30 April 2025 [5] - The settlement and delivery date for the New Bonds is anticipated to be on 6 May 2025 [6] Group 2: Use of Proceeds - The net proceeds from the issuance of the New Bonds will be utilized for general corporate purposes and the purchase of new cash-settled call options on VINCI's shares [4][3] Group 3: Market and Regulatory Context - The New Bonds will be offered through an accelerated book building process to institutional investors only, with no public offering in certain jurisdictions including the United States, Australia, South Africa, Canada, and Japan [9][18] - VINCI will agree to a lock-up undertaking regarding its shares and equity-linked securities for a period ending 60 days after the settlement date of the New Bonds [8]

Investment Plans - IBM announced plans to invest $150 billion in the United States over the next five years, with $30 billion specifically allocated for research and development to enhance manufacturing of mainframe and quantum computers [1][2][4] Strategic Positioning - The investment aims to solidify IBM's position as a leader in advanced computing and AI capabilities, as stated by IBM chairman and CEO Arvind Krishna [2][4] Industry Context - Other corporate giants like Apple, Nvidia, and Hyundai have also revealed significant spending plans in the U.S. since the return of President Trump to the White House, indicating a broader trend among major companies to invest domestically [3] - The investment comes amid a backdrop of tariff hikes aimed at encouraging U.S. companies to bring manufacturing back home, although many tariffs have been put on hold due to concerns about their impact on the economy [3]

Core Insights - Google (NASDAQ: GOOG) reported first quarter results for FY25 that exceeded Wall Street analysts' expectations, indicating strong performance and potential growth opportunities [1]. Financial Performance - The earnings release highlighted significant financial metrics that surprised analysts, suggesting a positive trend in revenue and profitability for the company [1]. Market Position - The company continues to maintain a competitive edge in the market, with analysts noting its ability to outperform expectations amidst a challenging economic environment [1]. Investment Opportunities - The results may present potential investment opportunities for stakeholders, particularly in light of the company's strong fundamentals and market positioning [1].

Company Overview - Société BIC is a global leader in stationery, lighters, and shavers, known for its commitment to delivering high-quality, affordable, and trusted products for 80 years [6] - The company operates in over 160 countries with a workforce of more than 13,000 employees, offering a portfolio of iconic brands and products [6] - BIC is listed on Euronext Paris and is included in the SBF120 and CAC Mid 60 indexes, highlighting its significant market presence [6] Upcoming Events - A Combined, Ordinary and Extraordinary, General Meeting is scheduled for May 20, 2025, at 9:30 a.m. in Paris [1] - The agenda and draft resolutions for the meeting were published in the French official legal announcement publication (BALO) No.42 on April 7, 2025 [2] - The Board of Directors amended the agenda and draft resolutions on April 23, 2025, including modifications to the titles and texts of specific resolutions [2][5] Communication and Contact Information - Investor Relations and Global Communications contacts are provided for inquiries, including Brice Paris and Bethridge Toovell [4] - Additional details regarding the changes to the meeting notice can be found on BIC's website under the "Investors/Shareholders Meetings" section [3]

Core Business Growth - Eurobio Scientific reported a revenue increase of 19% to €154.2 million in 2024, compared to €130 million in 2023, with organic growth at 9% [4][5][6] - Proprietary products accounted for 31% of total sales, remaining stable compared to the previous year, while international sales represented 41% of group revenue, up from 38% in 2023 [5][6] Financial Performance - Total operating income rose by 19% to €154.9 million, with a gross margin of 46.6%, down approximately 1% from 2023 due to pressure on margins and challenges faced by some European subsidiaries [4][7] - Adjusted EBITDA was €27.7 million, a slight increase from €27.3 million in 2023, while operating income was stable at €22.1 million [10][11] Cost Management - Research and development expenses decreased to €4.6 million, primarily due to reduced activity in France, while marketing and sales expenses increased by €10.1 million, driven by strengthening sales teams and new acquisitions [8] - General and administrative expenses rose by €1.8 million, attributed to new premises and acquisitions [8] Strategic Developments - The company completed the acquisition of EndoPredict® and Prolaris® in August 2024, generating sales of €3.8 million, although this was a 10% decline compared to 2023 [9] - Eurobio Scientific is focused on strategic priorities including the development of proprietary products, internationalization, and market expansion to enhance growth in sales and margins [16] Cash Flow and Debt Management - Free cash flow for 2024 was €6 million, with cash flow from operations amounting to €16.7 million [12][13] - At the end of December 2024, the company had cash and cash equivalents of €23.1 million and net debt of €3.9 million [15]

Group 1 - Austral Gold Limited is an established gold producer with a focus on building a portfolio of quality assets in the Americas through production, exploration, and equity investments [2] - The company's 2025 Annual General Meeting (AGM) is scheduled for Thursday, 29 May 2025, at 9:00 am AEST in Sydney, Australia [1][4] - Relevant documents for the AGM, including the Notice of AGM and proxy forms, have been dispatched to shareholders and are available on the ASX and the company's website [1][6] Group 2 - Austral Gold continues to advance its growth strategy by developing its attractive portfolio of producing and exploration assets [2][4] - The company is focused on three strategic pillars: production, exploration, and equity investments, which are essential for its growth [2]

Core Points - GTT has filed its 2024 Universal Registration Document, which includes the Annual Financial Report, with the French stock market authorities on April 25, 2025 [1] - The document is available in French and will soon be available in English on GTT's website [2] - The 2024 Universal Registration Document contains various reports, including the annual financial report, management report, sustainability information, corporate governance report, and details regarding the upcoming shareholders' meeting [4] Financial Agenda - The combined shareholders' meeting is scheduled for June 11, 2025 [4] - The ex-dividend date for the balance of the dividend for the 2024 financial year is June 17, 2025 [4] - Payment of the balance of the dividend for the 2024 financial year will occur on June 19, 2025 [4] - The publication of the 2025 half-year results is set for July 29, 2025, after market close [4] - The 2025 third-quarter results will be published on October 31, 2025, after market close [4] Company Overview - GTT specializes in the design and development of cryogenic membrane containment systems for the transport and storage of liquefied gases [3][5] - The company has over 60 years of experience and is recognized for its innovative technologies used in LNG carriers and other related applications [3][5] - GTT is committed to sustainability and develops solutions to support the transition to a decarbonized future, including systems that enable the use of LNG as fuel [5]

Core Viewpoint - Lumibird Group reported a consolidated revenue growth of 12.4% in Q1 2025, reaching €49.4 million, driven by strong performance in both the Photonics and Medical divisions [1][3]. Revenue Summary - Consolidated revenues for Q1 2025 were €49.4 million, an increase of 12.4% compared to €43.9 million in Q1 2024, with a constant exchange rate growth of 11.7% [3]. - The Photonics division generated €23.9 million, up 15.8% from €20.6 million in Q1 2024, with a constant exchange rate growth of 15.1% [3][4]. - The Medical division achieved revenues of €25.5 million, reflecting a growth of 9.4% from €23.3 million in Q1 2024, with a constant exchange rate growth of 8.6% [3][6]. Division Performance - The Defence/Space business within the Photonics division saw sales rise by 37.8% to €10.5 million, attributed to multi-year contracts and order book deliveries [4]. - Industrial and Scientific sales increased by 7.0% to €5.9 million, including €0.5 million from the Continuum range acquired in October 2024 [5]. - Medtech sales slightly declined by 2.3% to €3.9 million, impacted by the timing of deliveries throughout 2025 [5]. Geographical Breakdown - EMEA revenues for Photonics were €13.8 million, up 16.2%, while Medical revenues were €7.6 million, down 6.0% [7]. - In the Americas, Photonics revenues increased by 54.1% to €4.5 million, and Medical revenues rose by 2.1% to €6.6 million [7]. - Asia-Pacific Photonics revenues decreased by 17.5% to €2.9 million, while Medical revenues increased by 29.1% to €8.1 million [7]. Future Outlook - Lumibird anticipates continued business expansion driven by growth in Defence/Space and Medical markets, with no significant impact expected from increased customs barriers [10][11].

Core Insights - The market for remote management solutions in heating networks and Building Management Systems (BMS) is experiencing strong growth due to energy transition, urbanization, decarbonization, and rising energy costs [2][4][8] - LACROIX is well-positioned to capitalize on this growth with its IIoT solutions and has seen significant sales acceleration in its HVAC segment, which recorded a CAGR of 10% from 2021 to 2024 [4][6] - The BACS decree mandates the automation of commercial buildings starting January 1, 2025, but only 15% of buildings were equipped by 2024, indicating a significant market opportunity [3] Industry Overview - The number of district heating networks in France has doubled over the past decade, exceeding 1,000 networks in 2023, with over 50,000 substations [2] - The HVAC segment is a critical part of LACROIX's Environment activity, which integrates technological synergies to enhance service offerings [5][8] Company Positioning - LACROIX's end-to-end solutions and recognized service model make it a trusted partner for major operators like ENGIE Solutions and DALKIA [6] - The company aims for international development as a strategic pillar of its 2027 roadmap, leveraging its subsidiaries in Italy and Spain [7][8] - LACROIX's revenue reached €636 million in 2024, and it is ranked among the top 50 worldwide and top 10 European EMS [10]